💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

'Pharma bro' Shkreli barred from discussing trial around courthouse

Published 07/05/2017, 12:55 PM
© Reuters. Martin Shkreli, former chief executive officer of Turing Pharmaceuticals and KaloBios Pharmaceuticals Inc, departs after a hearing at U.S. Federal Court in Brooklyn, New York

By Brendan Pierson

(Reuters) - A U.S. judge on Wednesday ordered Martin Shkreli to stop talking about his fraud case in or around the Brooklyn courthouse where he is standing trial, five days after the former drug company executive burst into a room full of spectators and attacked the credibility of a government witness.

U.S. District Judge Kiyo Matsumoto's order did not bar Shkreli from making any public statements about the case, as prosecutors had requested in a motion filed Monday, according to John Marzulli, a spokesman for the prosecutors.

Shkreli, 34, gained notoriety in 2015 when he raised the price of a life-saving drug by 5,000 percent as CEO of Turing Pharmaceuticals, sparking outrage among patients and U.S. lawmakers and earning him the nickname "pharma bro."

The charges he now faces stem not from his time at Turing, but from his management of hedge funds MSMB Capital and MSMB Healthcare and of pharmaceutical company Retrophin Inc between 2009 and 2014.

Shkreli last week told reporters that an alleged victim of his was not actually a victim, because she made money from his investments, attorneys for the government said in Monday's motion.

He also directly spoke on camera to a journalist outside the courthouse, and appeared to be commenting on the case on Twitter under the handle @BLMBro, the prosecutors added. Shkreli previously used Twitter under his own name, but the social media platform banned him from doing so in January after he harassed a female journalist.

In seeking a broad gag order on Monday, prosecutors said Shkreli's repeated public statements about his case could taint the jury and make a fair trial impossible.

Shkreli's attorney, Benjamin Brafman, had opposed the prosecutors' request for a broad gag order, saying in a court filing that his client had a First Amendment right to speak freely.

Brafman also disclosed in court Wednesday that he had discussed a possible guilty plea with prosecutors before the trial, though he said Shkreli himself rejected the possibility, according to Marzulli.

Prosecutors have claimed that Shkreli ran a scheme in which he lied to lure investors in the MSMB funds, concealed huge trading losses from them and repaid them with millions of dollars stolen from Retrophin, where he was CEO.

© Reuters. Martin Shkreli, former chief executive officer of Turing Pharmaceuticals and KaloBios Pharmaceuticals Inc, departs after a hearing at U.S. Federal Court in Brooklyn, New York

Shkreli was ousted from Retrophin in 2014. He has denied the charges against him.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.